BMRN News and Headlines - Biomarin Pharmaceutical Inc

GuruFocus Articles Total 47
  • 1
  • 2
  • 3

The stock of Biomarin Pharmaceutical (NAS:BMRN, 30-year Financials) appears to be modestly undervalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its

0 Views    GF Value    2021-04-29 14:12

CEO of Biomarin Pharmaceutical Inc (30-Year Financial, Insider Trades) Jean Jacques Bienaime (insider trades) sold 20,000 shares of BMRN on 04/23/2021 at an average price of $79.13 a share. The total sale was $1.6 million.

For the complete insider trading history of BMRN, click here

.
0 Views    insider    2021-04-27 01:15

The stock of Biomarin Pharmaceutical (NAS:BMRN, 30-year Financials) gives every indication of being modestly undervalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value

0 Views    GF Value    2021-03-29 01:12
Guru adds to stake in biotech focused on cancer immunotherapies

Steven Cohen (Trades, Portfolio), the billionaire investor who leads Point72 Asset Management, disclosed earlier this week his firm upped its stake in Affimed NV (AFMD) by 190.73%.

The guru's Stamford, Connecticut-based firm invests in a wide range of asset classes worldwide in order to generate superior risk-adjusted returns. Its long-short strategy is based on bottom-up research processes focusing on fundamentals and macroeconomic conditions.

According to Real-Time Picks, a Premium feature of GuruFocus, Cohen invested in 3.8 million shares of the German biopharmaceutical company on Jan. 27. The stock traded for an average price of $5.72 per

459 Views    Sydnee Gatewood    2021-02-09 17:15
Guru invests in biotech focusing on cancer treatments

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm entered an 8.9% stake in CytomX Therapeutics Inc. (CTMX).

With the goal of generating superior risk-adjusted returns, the guru's Stamford, Connecticut-based firm invests in a wide range of asset classes worldwide. Its long-short strategy is based on bottom-up research processes focusing on fundamentals and macroeconomic conditions.

According to GuruFocus Real-Time Picks, a Premium feature, Cohen invested in 5.5 million shares of the San Francisco-based biopharmaceutical company on Jan. 25 after previously exiting a position in the third quarter of 2020. The stock

474 Views    Sydnee Gatewood    2021-01-27 17:43
Firm also upped FibroGen stake in December

Media-shy investment firm PRIMECAP Management (Trades, Portfolio) revealed earlier this week it curbed its stakes in two companies and added to its position in another on Dec. 31.

The California-based firm, which was founded in 1983, manages the Odyssey Funds. It seeks to provide long-term capital appreciation by investing in companies with stronger growth potential than their valuations suggest and that trade at reasonable prices.

According to GuruFocus Real-Time Picks, a Premium feature, Primecap reduced its Cree Inc. (CREE) stake by 46.45% and its BioMarin Pharmaceutical Inc. (BMRN) position by 0.24%. Its holding of FibroGen Inc.

250 Views    Sydnee Gatewood    2021-01-08 17:21
After slumping in 2020, biopharma deals are expected to jump in the new year

Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which was announced on Dec. 12. Industry observers are already predicting that, after the down year that was 2020, M&A activity will return to pre-Covid heights, according to an article in FiercePharma.

Fundamentals will be important, explained Arda Ural, Ph.D., Ernst & Young's Americas industry markets leader for health sciences and wellness. "Big Pharma companies have the balance sheets to deploy against M&A, and the need to go into

1012 Views    Barry Cohen    2020-12-24 17:38
Gene therapy acquisitions are one way for Big Pharma to up growth

Eli Lilly and Co. (LLY) recently showed its commitment to gene therapy when it signed a deal that could be worth $2.6 billion with Precision BioSciences Inc. (DTIL).

Several other smaller biotechs are developing this technology, which the pharmaceutical industry has identified as a high-growth area. Thus, these newer companies could be good candidates for similar deals or buyouts.

High on the list of gene therapy companies that investors expect to become acquisition targets soon are bluebird bio Inc. (BLUE) and Biomarin Pharmaceutical Inc. (BMRN), according to FierceBiotech.

Among the

395 Views    Barry Cohen    2020-12-17 15:00
Fund eliminates 2 positions and reduces 2 others

David Carlson (Trades, Portfolio), manager of Elfun Trusts, disclosed this week that his fund's top trades during the third quarter featured four sales, including the elimination of all shares in Biomarin Pharmaceutical Inc. (BMRN) and ASML Holding NV (ASML) and the reduction of holdings in Salesforce.com Inc. (CRM) and Amazon.com Inc. (AMZN).

The fund, with is part of State Street Global Advisors, seeks long-term capital appreciation in U.S. equity securities that have the potential to pay dividends in the future.

39a3c7eb6c9998b8ac9047f6fd8fac66.png

As of quarter-end, the fund's $3.06 billion equity portfolio contains 44

190 Views    James Li    2020-11-03 21:29
Firm's largest trades of the 3rd quarter

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) sold shares of the following stocks during its third quarter of fiscal 2020, which ended on Sept. 30.

Gilead Sciences

The fund closed its position in Gilead Sciences Inc. (GILD). The trade had an impact of -1.59% on the portfolio.

c5c0a927911fed3956550a5aeb996c32.png

The company, which develops therapies to treat life-threatening infectious diseases, has a market cap of $74.12 billion and an enterprise value of $79.42 billion.

GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on

86 Views    Tiziano Frateschi    2020-10-29 16:27
Health care-focused fund releases 3rd-quarter portfolio

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the third quarter of the year earlier this week.

Managed by Jason Kritzer and Samantha Pandolfi, the fund, which is part of Boston-based Eaton Vance, invests heavily in the health care space. The portfolio managers look around the world for securities that are not only reasonably priced, but which they believe will grow in value over time.

Although the fund added six new holdings to the portfolio during the three months ended Aug. 31, its most notable trades included an addition to its AbbVie

172 Views    Sydnee Gatewood    2020-10-28 19:48
Guru stock highlight

BioMarin Pharmaceutical (BMRN) , which develops pharmaceuticals for rare, often genetic, diseases, fell after an unexpected U.S. Food and Drug Administration (FDA) determination delayed the approval timeline for the company's hemophilia gene therapy, which we considered a key, near-term growth driver.

From [url=https://www.gurufocus.com/StockBuy.php?GuruName=Spiros+Segalas]Spiros Segalas[/url] ([url=https://www.gurufocus.com/StockBuy.php?GuruName=Spiros+Segalas]Trades[/url], [url=https://www.gurufocus.com/holdings.php?GuruName=Spiros+Segalas]Portfolio[/url])' Harbor Capital Appreciation Fund third-quarter 2020 commentary.

41 Views    Sydnee Gatewood    2020-10-20 22:09
Discussion of markets and holdings

MANAGER COMMENTARY

As of 09/30/2020

"The U.S. economy continues to recover from the worst effects of the pandemic, but the pace of the rebound appears to be moderating." Jennison Associates LLC

Market in Review

Equities markets continued their vigorous, post-March rally in the third quarter, as the realities of COVID-19 continued to dictate daily conduct for individuals, businesses, and governments around the world. Behaviors, which seemed disorienting and disruptive in the spring, became routine throughout the summer and early fall. Work-from-home remained the standard, while countries and enterprises experimented tentatively with reopenings. Global infection rates reflected varying policy and social

76 Views    Sydnee Gatewood    2020-10-20 21:57
Insiders load up on Kinder Morgan, Biomarin Pharmaceutical, Quidel and American Financial Group

The largest insider buys this week were Kinder Morgan Inc. (KMI), Biomarin Pharmaceutical Inc. (BMRN), Quidel Corp. (QDEL) and American Financial Group Inc. (AFG).

Kinder Morgan director bought 7,000 shares

Director William A. Smith bought 7,000 shares of Kinder Morgan on Aug. 31 for an average price of $13.96. The share price has decreased by 3.15% since then.

Kinder Morgan is an American energy infrastructure company that specializes in owning and controlling oil and natural gas pipelines and terminals. Currently, the company is the largest energy infrastructure company in North America and operates approximately 84,000 miles of pipelines and owns

1031 Views    Shuda Xia    2020-09-05 18:32
If approved, company's Roctavian would become first gene therapy for inherited disease

Five pharmaceutical companies are awaiting approval of drugs in the next few months, and Biomarin Pharmaceutical Inc. (BMRN) has the most to gain. If the company’s Roctavian gets greenlighted by the Food and Drug Administration, it will become the first gene therapy for one of the world’s highest-profile inherited diseases, hemophilia A.

Hemophilia is a rare hereditary bleeding disorder that occurs in a relatively small number of patients around the world. Its cause is a missing or deficient protein needed for blood clotting. Hemophilia A occurs in one in 5,000 live male births. It is about four times as common

231 Views    Barry Cohen    2020-07-09 18:57
French pharma giant seeks to exit heart and diabetes research and enter cancer and immune disease

Sanofi SA (SNY) has made it clear it wants to get into the rapidly growing gene therapy market, and an acquisition may be the fastest route. Rumor has it that the French pharmaceutical giant has its eyes on San Rafael, California-based Biomarin Pharmaceutical Inc. (BMRN).

Speculation heated up after Sanofi announced it was selling about $11 billion worth of shares it owns in Regeneron Pharmaceuticals Inc. (REGN). That would be a nice down payment, but Sanofi will have to dig deeper into its pockets because Biomarin has a market value of nearly $22 billion. Year to date, its shares are

245 Views    Barry Cohen    2020-06-25 18:26
Fund's new buys include Ackman holding Lowe's

David Carlson (Trades, Portfolio), manager of Elfun Trusts, disclosed this week that his fund’s top five buys in the first quarter included an increased bet in Facebook Inc. (FB) and new holdings in four companies: Lowe’s Companies Inc. (LOW), Biomarin Pharmaceutical Inc. (BMRN), Texas Instruments Inc. (TXN) and Mondelez International Inc. (MDLZ).

The fund, which is part of State Street Corp. (STT) subsidiary State Street Global Advisors, seeks long-term capital appreciation through investments in U.S. companies that have potential to pay good dividends in the future.

246642b259710908f60d8929ac5761e8.png

A former manager of the

751 Views    James Li    2020-05-01 21:26
Sands Capital Management exits positions in Biomarin, Palo Alto Networks

Sands Capital Management recently disclosed its portfolio updates for the fourth quarter of 2019.

Founded in 1992 by Frank M. Sands Sr., Sands Capital Management is a staff-owned independent investment management firm that invests in high-quality growth business. Frank Sands (Trades, Portfolio) Jr. joined the firm in 2000 and now serves as CEO and Chief Investment Officer. The Arlington, Virginia-based firm has two main concentrated growth strategies: Select Growth, which chooses innovative businesses, and Global Growth, which diversifies holdings in countries outside of the U.S. Sands Capital Management has achieved success by focusing on its six investment

182 Views    Margaret Moran    2020-02-18 22:22
The gene therapy company is expected to introduce hemophilia drug that is projected to generate revenue of $1.2 billion by 2024

With sales of $1.6 billion over the past year, BioMarin Pharmaceutical Inc. (BMRN) will get a hefty revenue boost with the introduction of its hemophilia A therapy, which is expected later this year.

Valrox is forecast to reach sales of more than $1.2 billion by 2024, according to pharmaceutical intelligence provider Evaluate. The San Francisco-based biotech’s application is currently being reviewed by regulators in the U.S. and Europe.

In anticipation of a 2020 launch, the company is gearing up manufacturing at its Novato, California plant, more than doubling capacity to 10,000 doses.

The upgrade is important “because first-mover advantage in

443 Views    Barry Cohen    2020-02-04 22:29
The immune-driven biotech company went public last June

Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed last week he trimmed the firm’s Adaptive Biotechnologies Corp. (ADPT) stake by 12.79%.

A protégé of Tiger Management’s Julian Robertson (Trades, Portfolio), Halvorsen’s Connecticut-based firm picks stocks based on its understanding of the business’ fundamentals and management team as well as cyclical and secular industry trends.

According to GuruFocus Real-Time Picks, a Premium feature, the guru sold 4.9 million shares of the Seattle-based biotech company on Jan. 28, bringing the total holding to 33.5 million shares, which represent 4.39% of the equity portfolio. The stock

157 Views    Sydnee Gatewood    2020-02-03 16:27

Headlines Total 209
  • 1
  • 2
  • 3

2021-05-11 $ 76.39 (-1.77%)
10:15pm
2021-04-30 $ 77.92 (-2.82%)
8:58am
2021-04-29 $ 80.18 (-0.35%)
4:25pm
9:12am
2021-04-27 $ 81.16 (3.09%)
8:15pm
2021-04-22 $ 79.7 (0.47%)
11:33am
2021-03-29
8:12pm
2021-03-27
10:31am
2021-03-16 $ 78.39 (2.11%)
9:15pm
2021-03-15 $ 78.39 (2.11%)
5:52am
2021-03-09 $ 78.74 (2.81%)
8:05am
2021-02-26 $ 77.43 (-5.3%)
8:16am
3:47am
2021-02-23 $ 81.06 (-0.86%)
8:15pm
2021-02-20 $ 81.76 (-1.81%)
10:15pm
2021-02-19 $ 83.27 (-2.95%)
9:15pm
2021-02-18 $ 83.27 (-2.95%)
11:33am
2021-02-17 $ 84.94 (-2.41%)
10:38pm
2021-02-12 $ 87.04 (0.21%)
5:25am
2021-02-11 $ 86.86 (1.65%)
10:40am
2021-02-04 $ 84.81 (2.4%)
7:24am
2021-02-02 $ 83 (0.27%)
8:15pm
2021-01-29 $ 83.15 (-0.11%)
10:15pm
2021-01-26 $ 85.91 (-3.44%)
10:40am
2021-01-22 $ 87.99 (1.28%)
7:55am
2021-01-12 $ 81.12 (-0.15%)
8:24am
2021-01-11 $ 81.24 (-9.59%)
7:37am
2021-01-07 $ 90.69 (3.36%)
10:40am
2020-12-18 $ 88.85 (-1.5%)
11:14am
2020-12-17 $ 90.2 (1.03%)
8:42am
2020-12-05
10:32am
2020-11-24 $ 77.96 (1.19%)
11:00am
10:39am
2020-11-23 $ 77.04 (1.44%)
11:01am
2020-11-20 $ 75.95 (1.09%)
7:00am
2020-11-19 $ 75.13 (1.29%)
3:00pm
11:01am
11:00pm
2020-11-18 $ 76.53 (-0.75%)
11:00pm
8:38pm
2020-11-16 $ 77.11 (-0.53%)
11:00am
9:07am
2020-11-13 $ 77.52 (0.79%)
11:00am
12:38am
2020-11-12 $ 76.91 (0.91%)
3:00pm
2020-11-10 $ 76.18 (1.45%)
9:34am
2020-11-08
3:00am
2020-11-07
3:00pm
1:12am
2020-11-06 $ 76.74 (2.25%)
9:57am
7:07am
6:02am
2020-11-05 $ 75.05 (-1.73%)
4:35pm
3:00pm
2020-11-04 $ 76.37 (5.18%)
3:00pm
2020-11-03 $ 72.61 (-1.1%)
3:29pm
6:20am
11:00pm
2020-11-02 $ 73.42 (-1.36%)
3:00pm
2020-10-29 $ 74.42 (0.04%)
3:00pm
11:35am
2020-10-28 $ 74.39 (-2.35%)
11:01am
2020-10-27 $ 76.18 (-0.91%)
11:01am
11:00pm
7:01pm
2020-10-26 $ 76.88 (-0.84%)
4:50pm
2020-10-25
3:00pm
2020-10-22 $ 77.5 (-0.53%)
7:02pm
7:00pm
2020-10-21 $ 77.5 (-0.53%)
11:33am
11:00pm
2020-10-20 $ 77.91 (0.75%)
5:09pm
11:00pm
2020-10-19 $ 77.33 (-2.42%)
3:00pm
2020-10-15 $ 77.67 (-1.42%)
11:00am
11:00pm
2020-10-14 $ 78.79 (-1.36%)
11:00am
11:00pm
7:00pm
2020-10-13 $ 79.88 (0.04%)
12:38pm
11:00pm
7:00pm
2020-10-09 $ 79.61 (2.44%)
11:00pm
2020-10-08 $ 79.61 (2.44%)
12:08pm
11:01am
2020-10-06 $ 75.55 (-1.88%)
3:00pm
2020-10-04
7:00pm
2020-09-30 $ 76.08 (0.11%)
3:00pm
7:01pm
7:00pm
2020-09-29 $ 76 (-2.55%)
10:04am
11:00pm
2020-09-28 $ 77.99 (0.78%)
11:01am
2020-09-25 $ 77.39 (1.06%)
12:54pm
6:53am
2020-09-24 $ 76.58 (-2.36%)
2:09pm
7:48am
2020-09-11 $ 72.05 (0.25%)
12:54pm
2020-09-09 $ 74.49 (%)
12:57pm
2020-09-08 $ 74.49 (-1.99%)
6:01am
Total 209
  • 1
  • 2
  • 3